Andrew Adams, PhDVice President, New Therapeutic Modalities at Eli Lilly & Company
Dr. Andrew C. Adams serves as Vice President for Lilly’s New Therapeutic Modalities department. In this role, Andrew is responsible for leading the discovery of new types of therapies, such as genetic medicines, at Lilly via both internal research and robust collaborations with external partners.
In addition to this role, in 2020 Andrew also took on scientific leadership of Lilly’s COVID-19 neutralizing antibody projects, which are now in late stage clinical trials. This role has involved partnership inside and outside of Lilly’s walls, to deliver the first purpose made therapy for COVID-19 to the clinic in less than 3 months from its discovery.
These novel approaches will allow access to previously undruggable targets across the breath of therapeutic areas at Lilly, as well as potentially opening up novel avenues of clinical investigation.
Andrew holds a degree in biology and a doctorate in zoology from the University of Aberdeen, Scotland. Prior to joining Lilly in 2011, Andrew was a postdoctoral fellow at Harvard Medical School. Through his roles in early discovery, external innovation and as a leader of Lilly’s trailblazer teams Andrew is well recognized as an innovative and collaborative scientific leader.